why choose us

300×250 Ad Slot

Research Article: Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

Date Published: 2026-07-14

Abstract:
Denosumab is an effective antiresorptive therapy for postmenopausal osteoporosis; however, long-term real-world data regarding sustained efficacy, treatment adherence, safety, and biochemical outcomes remain limited. This study evaluated the 36-month effectiveness and safety of denosumab in postmenopausal women with osteoporosis receiving routine clinical care. This retrospective analysis included a prospectively followed real-world clinical cohort of 130 postmenopausal women with osteoporosis treated with denosumab (60?mg subcutaneously every 6?months) plus calcium and vitamin D supplementation. Participants were followed for 36?months with assessments at baseline, 12, 24, and 36?months. Outcomes included bone mineral density (BMD), T-scores, bone turnover markers, renal function, adherence patterns, prior treatment history, fracture occurrence, and adverse events. Changes over time were analyzed using paired longitudinal comparisons and linear mixed-effects models, with significance defined as p <?0.05. Lumbar spine (L1–L4) BMD increased from 0.674?±?0.120 to 0.741?±?0.102?g/cm 2 , while femoral neck BMD increased from 0.526?±?0.086 to 0.562?±?0.079?g/cm 2 over 36?months (both p <?0.001). BMD improvements were accompanied by reductions in bone turnover markers, including ? -CTX and PINP, indicating sustained suppression of bone resorption. No clinically meaningful renal deterioration was observed during follow-up. Twenty-one participants had prior osteoporosis treatment history, whereas all included patients completed seven denosumab injections. Delayed injections occurred in 29 patients, although most delays were <30?days. No new fragility fractures occurred during follow-up. No cases of osteonecrosis of the jaw, atypical femoral fracture, or injection-related serious adverse events were observed. Mild hypocalcemia occurred in several patients and resolved with monitoring and supplementation adjustment. Thirty-six months of denosumab treatment was associated with sustained improvement in BMD, suppression of bone turnover, acceptable adherence, and a favorable safety profile in postmenopausal women with osteoporosis who completed the planned 36-month treatment course. Because only patients completing all seven injections with complete follow-up data were included, adherence, persistence, and safety outcomes may be overestimated compared with an intention-to-treat population. These findings support the effectiveness of denosumab under routine clinical practice while emphasizing the importance of continued monitoring and adherence management.

Introduction:
Denosumab is an effective antiresorptive therapy for postmenopausal osteoporosis; however, long-term real-world data regarding sustained efficacy, treatment adherence, safety, and biochemical outcomes remain limited. This study evaluated the 36-month effectiveness and safety of denosumab in postmenopausal women with osteoporosis receiving routine clinical care.

Read more

300×250 Ad Slot